BRIEF published on 04/07/2026 at 07:05, 7 days 1 hour ago Aelis Farma obtient une subvention de 458 000 € pour son programme de lutte contre l'obésité France 2030 Aelis Farma Récepteur CB1 Recherche Sur L'obésité Subvention De Nouvelle-Aquitaine
BRIEF published on 04/07/2026 at 07:05, 7 days 1 hour ago Aelis Farma Secures €458k Grant for Obesity Program France 2030 Aelis Farma Obesity Research CB1 Receptor Nouvelle-Aquitaine Grant
PRESS RELEASE published on 04/07/2026 at 07:00, 7 days 1 hour ago Informations privilégiées / Autres communiqués Aelis Farma reçoit 458 k€ de subvention de France 2030 en Nouvelle-Aquitaine pour son programme innovant dans l'obésité et les maladies métaboliques. Soutien non dilutif pour la recherche sur les traitements des désordres métaboliques Subvention France 2030 Obésité Aelis Farma Nouvelle-Aquitaine
PRESS RELEASE published on 04/07/2026 at 07:00, 7 days 1 hour ago Inside Information / Other news releases Aelis Farma receives €458k grant under France 2030 for obesity program development, reinforcing innovation potential in metabolism field Metabolic Diseases Grant France 2030 Obesity Aelis Farma
BRIEF published on 03/21/2026 at 10:10, 23 days 22 hours ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
BRIEF published on 03/21/2026 at 10:10, 23 days 22 hours ago Aelis Farma fait progresser son essai clinique de phase 2B pour le traitement du syndrome de Down Essai Clinique AEF0217 Syndrome De Down Récepteur CB1 Comportement Adaptatif
PRESS RELEASE published on 03/21/2026 at 10:05, 23 days 22 hours ago Informations privilégiées / Autres communiqués Aelis Farma lance avec succès l'étude clinique de Phase 2B avec AEF0217 pour traiter les troubles comportementaux et cognitifs du syndrome de Down. Recrutement actif en France, Italie et Espagne Phase 2b Étude Clinique Aelis Farma AEF0217 Syndrome De Down
PRESS RELEASE published on 03/21/2026 at 10:05, 23 days 22 hours ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 3 months 2 days ago Aelis Farma obtient un avis favorable de l'EMA pour AEF0217 dans la trisomie 21 EMA Aelis Farma Trisomie 21 AEF0217 Développement Pédiatrique
BRIEF published on 01/12/2026 at 07:35, 3 months 2 days ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
Published on 04/13/2026 at 23:15, 9 hours 39 minutes ago Relevant Gold Completes Strategic Financing; Embarks on Largest Drilling Program in Company History
Published on 04/13/2026 at 23:00, 9 hours 54 minutes ago Sterling Metals Announces Sale Of Sail Pond Project
Published on 04/13/2026 at 22:25, 10 hours 29 minutes ago Findev Inc. Announces Dividend Updates Ex-Dividend Date
Published on 04/13/2026 at 16:00, 16 hours 54 minutes ago Norsemont To Participate in The Inaugural Swiss Mining Institute Conference in Panama City April 15-16
Published on 04/14/2026 at 08:30, 24 minutes ago New HQ business centre at Science Park North43: ESPG launches first project with IWG in Cologne
Published on 04/14/2026 at 08:30, 24 minutes ago CMC Markets partners with Upvest to launch multi-currency securities in Germany
Published on 04/14/2026 at 08:29, 25 minutes ago Anemoi enters into amended and updated binding Sale and Purchase Agreement to acquire Trasna, Share Consolidation and Warrantholder Surrender and Subscription Offer
Published on 04/14/2026 at 08:05, 49 minutes ago Omio launches in ChatGPT, bringing its real-time multimodal travel search to 900 million users
Published on 04/14/2026 at 08:00, 54 minutes ago Fuller, Smith & Turner PLC: Appointment of Joint Corporate Broker
Published on 04/14/2026 at 08:30, 24 minutes ago ALPOU - Groupe POULAILLON - Projet offre publique d'achat obligatoire
Published on 04/13/2026 at 19:14, 13 hours 39 minutes ago ALTAREA - Déclaration d’opérations sur actions propres
Published on 04/13/2026 at 18:15, 14 hours 39 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/03/2026
Published on 04/13/2026 at 18:15, 14 hours 39 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/03/2026
Published on 04/13/2026 at 18:09, 14 hours 45 minutes ago Infotel : Cessation et mise en œuvre d’un nouveau contrat de liquidité avec Invest Securities.
